Cytokinetics' Myqorzo Receives FDA Approval for Treatment
What happened
Myqorzo received approval from the FDA on September 23, 2026. This approval is part of the FDA's process for approving drugs developed by Cytokinetics for their intended use as a treatment.
From yahoo.com
Why it matters
The regulatory approval grants market access for Myqorzo, which could boost revenue for Cytokinetics. This new product also presents a direct competitive challenge to Bristol-Myers Squibb.
The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.
From yahoo.com
Who's involved
- FDAThe regulatory agency that granted approval to the drug.
- CytokineticsThe biopharmaceutical company that developed the approved drug.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- CytokineticsSpeculative
Cytokinetics could see an increase in revenue due to the market access granted by the FDA approval.
Keep exploring
The entities involved
- FDA
-
Cytokinetics
company in South San Francisco, United States
Related events
- Leerink and Stifel analysts commented on efficacy data following the separation of Myqorzo from the Camzyos market.
- The FDA upheld the De Novo denial for DrugSorb-ATR, a product of CytoSorbents. Phillip Chan serves as the company's CEO.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- The FDA approved Zenbexus oral therapy for multiple myeloma, coinciding with disclosures regarding insider buying and selling transactions.